FOLH1 and posterior cortical atrophy: There was consensus that for primary staging of favourable intermediate-risk PCa, no metastatic screening should be performed (85%), and that metastatic screening using PSMA-PET-based imaging should be performed for patients with unfavourable intermediate-risk (97%) or high-risk (100%) PCa (Table 1).